Show:
Disease State
Cabo/METEOR
Sunitinib/Sorafenib
Everolimus
Pazopanib/Axitinib
100
The 5-year survival rate for stage IV RCC
What is 0-20%
100
The comparator arm of the METEOR study
What is everolimus
100
The primary endpoints in the Nexavar phase 3 trial in patients with advanced RCC who had received one prior systemic therapy
What are PFS and OS
100
According to the package insert, hepatic impairment will __________ the exposure to everolimus
What is increase
100
The two treatment regimens on the AXIS trial
What are axitinib and sorafenib
200
The most common site of metastatic disease in RCC patients
What are the lungs
200
The week 16 DCR (disease control rate) in the RCC cohort of the Drug/Drug Interaction study
What is 72%
200
The PFS for patients receiving Sunitinib in the phase 3 study vs IFN
What is 11 months
200
The disease contral rate for the RECORD-1 everolimus vs placebo trial was
What is 64%
200
The dose and schedule for INLYTA
What is 5 mg orally twice daily approximately 12 hours apart with or without food
300
Before targeted agents, cytokine-based therapy was associated with a median PFS of _______ and median OS of ______
What are 3-5 months and 13 months
300
The two most frequently reported adverse events reported on the Drug/Drug Interaction study
What are fatigue and diarrhea
300
According to the sorafenib package insert, blood pressure should be monitored in this manner
What is weekly during the first 6 weeks of therapy then monitor an treat HTN if required according to standard medical practice
300
The two most common adverse events occurring in the everolimus group on the phase 3 study were
What are stomatitis and rash (updated information stomatitis and infection)
300
The median PFS for the two arms of the AXIS trial
What are 6.7 months for axitinib and 4.7 months for sorafenib (updated 8.3 mos vs 5.7 mos)
400
The function of the VHL gene is often lost in _______ percentage of non-hereditary RCC
What is > 50%
400
The starting dose for Cabozantinib and Everolimus in the METEOR trial
What are 60 mg and 10 mg
400
Nexavar dose may be reduced to
What is 400 mg once daily or to 400 mg every other day
400
The most common hematologic lab abnormality in the RECORD-1 trial
What is decreased HGB/anemia
400
The PFS for the overall treatment population and the cytokine-pre-treated population for those patients receiving pazopanib in the phase 3 trial
What is 9.2 months and 7.4 months
500
Name two prognostic survival factors for RCC patients with metastatic disease
What are long disease-free interval from initial nephrectomy, pulmonary metastases only, good PS and removal of the primary tumor
500
Randomization for the METEOR study will be stratified by the following factors
What are prior VEGFR-targeting TKI therapy 1 vs > 2 and MSKCC prognostic criteria for previously treated RCC patients 0 vs 1 vs 2 or 3
500
Sutent dose interruption and/or dose modifications in _________ increments or decrements is recommended based on individual safety and tolerability
What is 12.5 mg
500
The number of CRs on the RECORD-1 trial
What is none
500
The 3 most common treatment-emergent adverse events for patients enrolled on the pazopanib arm
What are diarrhea, hypertension and hair color changes